Standout Papers

T-Cell–Inflamed Gene-Expression Profile, Prog... 2009 2026 2014 2020 630
  1. T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028 (2018)
    Patrick A. Ott, Yung‐Jue Bang et al. Journal of Clinical Oncology
  2. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study (2020)
    Shanu Modi, Haeseong Park et al. Journal of Clinical Oncology
  3. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study (2009)
    Narikazu Boku, Seiichiro Yamamoto et al. The Lancet Oncology
  4. Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study (2014)
    Taroh Satoh, Rui‐Hua Xu et al. Journal of Clinical Oncology
  5. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study (2017)
    Toshihiko Doi, Kohei Shitara et al. The Lancet Oncology
  6. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE‐158 and KEYNOTE‐028 studies (2020)
    Sarina A. Piha‐Paul, Do‐Youn Oh et al. International Journal of Cancer
  7. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study (2019)
    Kenji Tamura, Junji Tsurutani et al. The Lancet Oncology
  8. Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors (2021)
    Giuseppe Curigliano, Hans Gelderblom et al. Clinical Cancer Research
  9. Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors (2020)
    Junji Tsurutani, Hiroji Iwata et al. Cancer Discovery
  10. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study (2022)
    Michele Maio, Paolo A. Ascierto et al. Annals of Oncology

Immediate Impact

4 by Nobel laureates 5 from Science/Nature 87 standout
Sub-graph 1 of 19

Citing Papers

Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
2024 Standout
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
2023 StandoutNobel
30 intermediate papers

Works of Toshihiko Doi being referenced

Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer
2019
Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment
2018
and 22 more

Author Peers

Author Last Decade Papers Cites
Toshihiko Doi 9051 6183 3514 421 13.9k
Kohei Shitara 8895 6534 3121 495 13.5k
Jeeyun Lee 7417 6559 3005 502 14.0k
Antoîne Italiano 8717 8842 2536 606 16.8k
Taroh Satoh 6611 6202 2780 292 11.6k
Josef Rüschoff 8758 6038 3282 220 14.9k
Johanna C. Bendell 9252 4273 2013 530 14.4k
Jayesh Desai 7478 4816 1965 317 12.9k
Ho Yeong Lim 6235 5478 3273 365 14.2k
Silvana Pilotti 6524 5255 2609 293 15.9k
Laura H. Tang 8963 3870 4508 288 15.2k

All Works

Loading papers...

Rankless by CCL
2026